A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancer-Reference-Cited by-同舟云学术

A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancer

Published:2023-04 Issue:4 Volume:4 Page:101015
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Liu Jinghui^ORCID,Zhao Yue,He Daheng,Jones Katelyn M.,Tang Shan,Allison Derek B.,Zhang Yanquan,Chen Jing,Zhang Qiongsi,Wang Xinyi,Li Chaohao,Wang Chi,Li Lang,Liu Xiaoqi

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference57 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of Incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA A Cancer J. Clin.,2021

2. Advanced prostate cancer: treatment advances and future directions;Swami;Trends Cancer,2020

3. Enzalutamide with standard first-line therapy in metastatic prostate cancer;Davis;N. Engl. J. Med.,2019

4. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer;Hussain;N. Engl. J. Med.,2018

5. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer;Watson;Nat. Rev. Cancer,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Casein Kinase 1α—A Target for Prostate Cancer Therapy?;Cancers;2024-07-02

2. Preclinical Anticipation of On- and Off-Target Resistance Mechanisms to Anti-Cancer Drugs: A Systematic Review;International Journal of Molecular Sciences;2024-01-05

3. Targeting the Metabolic Enzyme PGAM2 Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer by Inhibiting BCL2 Signaling;Cancer Research;2023-09-07